Abstract Details

Title New Insights on the Neuroprotective Role of Albumin for Acute Stroke Based on a Study of the Transition Zone between the Penumbra and Core

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P01 - (-)

Poster/Presentation
Number 251

Objective

Background BACKGROUND: Albumin is currently in clinical trial as a potential neuroprotective agent for acute ischemic stroke. We have developed a HypoxyProbe-1 (HP-1) based animal penumbra model and have demonstrated with immunohistochemistry that the presence of albumin covers the entire area of the ischemic core consistent with damage to the blood brain barrier. Albumin was also noted within the penumbra at the transition between the penumbra and the ischemic core. By studying the molecular events in this penumbra - core transition zone, we can study the possible effect of albumin on the tissue ischemic process.

Design/Methods DESIGN/METHODS: This study is in compliance with NIH animal care guidelines and was approved by the Purdue Animal Care and Use Committee. Sixteen Sprague-Dawley rats of both genders, aged 3-21 months were used. Five-hour intraluminal middle cerebral artery occlusion (MCAo) without reperfusion was induced under ketamine and xylazine. Physiologic parameters were monitored. Cerebral blood flow was measured with a laser Doppler system. HP-1 (60mg/kg) was injected intraperitoneally 90 minutes before sacrifice.

Results RESULTS: Double labeling immunohistochemical staining showed no co-localization of albumin with Iba1 (an activated microglial marker), ICAM-1 (an inflammatory marker), MetO (methionine sulfoxide, an early oxidative stress marker), and CCP-3 (an early apoptotic marker).

Conclusions CONCLUSIONS: Our results specifically evaluated the molecular events occurring at the penumbra-core transition zone. These findings support the potential benefits of albumin in acute ischemia through multiple mechanisms including inhibition of inflammation, early microglial activation, oxidative stress, and apoptosis.

Authors/Disclosures
Benecia Hong-Goka, MD PRESENTER	No disclosure on file
	No disclosure on file
Fen-Lei F. Chang, MD, PhD (Parkview Neuroscience)	Dr. Chang has nothing to disclose.
David S. Knopman, MD, FAAN (Mayo Clinic)	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.

��ɫ��

��ɫ��